Skip to main content

Table 1 Baseline demographics and comparison of demographics according to genotypes

From: Association between plasma sRAGE and emphysema according to the genotypes of AGER gene

 

Total

N = 436

CC*

n = 290

TC + TT*

n = 146

P

Age, years

72.3 ± 7.1

72.4 ± 7.1

72.2 ± 7.2

0.710

Sex, male, n (%)

316 (72.5)

218 (75.2)

98 (67.1)

0.075

Emphysema index

5.6 ± 6.3

6.5 ± 0.3

4.7 ± 0.5

0.002

Presence of emphysema

   

0.020

 Emphysema (−)

287 (65.8)

180 (62.1)

107 (73.3)

 

 Emphysema (+)

149 (34.2)

110 (37.9)

39 (26.7)

 

COPD, n (%)

   

0.040

 Non-COPD

156 (35.8)

93 (32.0)

63 (43.2)

 

 GOLD Stage 1

20 (4.6)

12 (4.1)

8 (5.5)

 

 GOLD Stage 2

143 (32.8)

92 (31.7)

51 (34.9)

 

 GOLD Stage 3

118 (27.0)

90 (31.0)

28 (18.2)

 

Smoking status, n (%)

   

0.046

 Current

96 (22.1)

72 (24.9)

24 (16.5)

 

 Former

180 (41.5)

122 (42.2)

58 (40.0)

 

 Never

158 (36.4)

95 (32.9)

63 (43.5)

 

Smoking, Pack-years

17.1 ± 22.8

18.1 ± 22.4

15.2 ± 23.6

0.223

Education

   

0.304

 < Elementary school

132 (31.1)

90 (31.9)

42 (29.4)

 

 Elementary school

164 (38.6)

101 (35.8)

63 (44.0)

 

 Middle school

63 (14.8)

38 (13.5)

25 (17.5)

 

 ≥ High school

66 (15.5)

53 (18.8)

13 (9.1)

 

sRAGE, pg/mL

666.7 ± 338.8

720.9 ± 341.4

558.9 ± 307.5

 < 0.001

Log sRAGE

6.4 ± 0.4

6.4 ± 0.4

6.2 ± 0.5

 < 0.001

  1. Categorical variables are expressed as number (%) and continuous variables are expressed as mean ± standard deviation
  2. COPD chronic obstructive pulmonary disease, sRAGE soluble receptor for advanced glycation end products
  3. *Genotypes of rs2060700